One-day point prevalence of healthcare-associated infections and antimicrobial use in four countries in Latin America

• Autor(a) principal: R.huerta-gutiérrez
• Data de Publicação: 2019
• Outros Autores: Rayo Morfín-otero, p. Rodríguez-zulueta, a. Rosado-buzzo, Fernando Rosso-suárez, Wanessa Trindade Clemente, Denusa Wiltgen, l. Braga, a. Camacho-ortiz, Humberto Díaz-ponce, l. García-mollinedo, m. Guzmán-blanco, s. Valderrama-beltrán, e. Landaeta-nezer, s. Moreno-espinosa
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UFMG
• Texto Completo: http://hdl.handle.net/1843/55711; https://orcid.org/0000-0003-0848-3740
• topic: Healthcare-associated infections; Antibiotics; One day prevalence; Public hospitals; Infectious Disease Medicine; Nosocomial infections; Infecção Hospitalar; Antibacterianos; Hospitais Públicos; infectologia

Background and aims: Experience in the region shows that in some countries there is very good surveillance of Healthcare-associated infections (HAIs) in health services, but there is no national data consistently in all countries. Therefore, we set to estimate the total burden of HAIs and antimicrobial use in acute care hospitals in Brazil, Venezuela, Mexico, and Colombia using the one-day point prevalence methodology. Methods: The survey was conducted between June and July 2016. In each ward or unit, HAIs and antimicrobial use data were collected on a single day by a trained team of researchers. Also, for each patient, we collected data on risk factors for infections. Results: One out of ten individuals surveyed had at least one healthcare-associated infection (HAI).Pneumonia and surgical site infections were the most relevant among the surveyed countries. Most of the surveyed participants, regardless of their HAI status, received antibiotics except the individuals managed in Brazil. Carbapenems and third-generation Cephalosporins were among the most frequently used antibiotics. Conclusion: Our results add to WHO’s recent efforts to understand HAIs prevalence and antibiotic consumption in low and middle-income countries, of which we studied three that were not included in their last report.